delandistrogene moxeparvovec-rokl
| Brand name | ELEVIDYS |
|---|---|
| Active ingredient | delandistrogene moxeparvovec-rokl |
| Strength | 1.33 10E14 vector genomes (vg)/kg/bodyweight(bw) |
| Dosage form | Suspension |
| Route | Intravenous |
| Modality | Biologic |
| FDA approval | June 2023 |
| Marketing status | Rx |
Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.